NATH BIOGENES (INDIA) Financial Statement Analysis
|
||
|
The Revenues of NATH BIOGENES (INDIA) have increased by 9.71% YoY .
The Earnings Per Share (EPS) of NATH BIOGENES (INDIA) has decreased by -2.59 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
NATH BIOGENES (INDIA) Last 5 Annual Financial Results
[BOM: 537291|NSE : NATHBIOGEN]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2013 |
|---|---|---|---|---|---|
| Revenues | ₹365 Cr | ₹333 Cr | ₹301 Cr | ₹278 Cr | ₹138 Cr |
| Expenses | ₹315 Cr | ₹283 Cr | ₹252 Cr | ₹241 Cr | ₹118 Cr |
| Operating Profit (Excl OI) | ₹50 Cr | ₹50 Cr | ₹49 Cr | ₹37 Cr | ₹20 Cr |
| Other Income | ₹4.55 Cr | ₹0.63 Cr | ₹0.55 Cr | ₹1.85 Cr | ₹0.58 Cr |
| Interest | ₹11 Cr | ₹9.21 Cr | ₹10 Cr | ₹11 Cr | ₹3.67 Cr |
| Depreciation | ₹3.82 Cr | ₹3.26 Cr | ₹3.01 Cr | ₹3.08 Cr | ₹4.51 Cr |
| Profit Before Tax | ₹41 Cr | ₹42 Cr | ₹36 Cr | ₹-63 Cr | ₹12 Cr |
| Profit After Tax | ₹39 Cr | ₹40 Cr | ₹35 Cr | ₹-67 Cr | ₹12 Cr |
| Consolidated Net Profit | ₹39 Cr | ₹40 Cr | ₹35 Cr | ₹-67 Cr | ₹12 Cr |
| Earnings Per Share (Rs) | ₹20.31 | ₹20.85 | ₹18.43 | ₹-35.46 | ₹7.34 |
| PAT Margin (%) | 10.58 | 11.91 | 11.62 | -24.21 | 8.53 |
| ROE(%) | 6.15 | 6.70 | 6.28 | -22.48 | 22.76 |
| ROCE(%) | 6.89 | 7.26 | 7.09 | -14.84 | 23.88 |
| Total Debt/Equity(x) | 0.19 | 0.18 | 0.18 | 0.17 | 0.33 |
Key Financials |
||
| Market Cap | : | ₹ 326.7 Cr |
| Revenue (TTM) | : | ₹ 404.7 Cr |
| Net Profit(TTM) | : | ₹ 39.9 Cr |
| EPS (TTM) | : | ₹ 21.0 |
| P/E (TTM) | : | 8.2 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| NATH BIOGENES (INDIA) | -1.4% | -13.6% | -20.2% |
| BOMBAY BURMAH TRADING CORPORATION | -0.5% | -8.3% | -17.3% |
| KAVERI SEED COMPANY | 3% | -4.1% | 1.6% |
| VENKYS (INDIA) | -7.2% | -11.7% | -37.1% |
| BOMBAY SUPER HYBRID SEEDS | -2.5% | -7.2% | -32.8% |
| INDO US BIOTECH | -5.9% | 0.7% | -26.9% |
| MANGALAM GLOBAL ENTERPRISE | 1.7% | -1.8% | NA |
| HARRISONS MALAYALAM | -0.4% | 1.7% | -8.5% |
| TIERRA AGROTECH | -3.2% | -0.4% | -44.6% |
NATH BIOGENES (INDIA) Revenues
[BOM: 537291|NSE : NATHBIOGEN]
| Y-o-Y | 9.71 % |
| 5 Yr CAGR | 27.59 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹365 Cr | 9.71 | |
| Mar2024 | ₹333 Cr | 10.37 | |
| Mar2023 | ₹301 Cr | 8.26 | |
| Mar2022 | ₹278 Cr | 102.15 | |
| Mar2013 | ₹138 Cr | - | |
NATH BIOGENES (INDIA) Operating Profit
[BOM: 537291|NSE : NATHBIOGEN]
| Y-o-Y | 0.02 % |
| 5 Yr CAGR | 25.88 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹50 Cr | 0.02 | |
| Mar2024 | ₹50 Cr | 1.99 | |
| Mar2023 | ₹49 Cr | 31.59 | |
| Mar2022 | ₹37 Cr | 87.05 | |
| Mar2013 | ₹20 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -8.85 % |
| 5 Yr CAGR | -1.34 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 13.69% | -8.85 | |
| Mar2024 | 15.02% | -7.57 | |
| Mar2023 | 16.25% | 21.54 | |
| Mar2022 | 13.37% | -7.47 | |
| Mar2013 | 14.45% | - | |
NATH BIOGENES (INDIA) Profit After Tax
[BOM: 537291|NSE : NATHBIOGEN]
| Y-o-Y | -2.57 % |
| 5 Yr CAGR | 34.64 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹39 Cr | -2.57 | |
| Mar2024 | ₹40 Cr | 13.11 | |
| Mar2023 | ₹35 Cr | Positive | |
| Mar2022 | ₹-67 Cr | Negative | |
| Mar2013 | ₹12 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -11.17 % |
| 5 Yr CAGR | 5.53 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 10.58 % | -11.17 | |
| Mar2024 | 11.91 % | 2.50 | |
| Mar2023 | 11.62 % | Positive | |
| Mar2022 | -24.21 % | Negative | |
| Mar2013 | 8.53 % | - | |
NATH BIOGENES (INDIA) Earnings Per Share (EPS)
[BOM: 537291|NSE : NATHBIOGEN]
| Y-o-Y | -2.59 % |
| 5 Yr CAGR | 28.97 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹20 | -2.59 | |
| Mar2024 | ₹21 | 13.13 | |
| Mar2023 | ₹18 | Positive | |
| Mar2022 | ₹-35 | Negative | |
| Mar2013 | ₹7.34 | - | |
NATH BIOGENES (INDIA) Return on Capital Employed (ROCE)
[BOM: 537291|NSE : NATHBIOGEN]
| Y-o-Y | -5.10 % |
| 5 Yr CAGR | -26.71 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 6.89% | -5.10 | |
| Mar2024 | 7.26% | 2.40 | |
| Mar2023 | 7.09% | Positive | |
| Mar2022 | -14.84% | Negative | |
| Mar2013 | 23.88% | - | |
NATH BIOGENES (INDIA) Share Price vs Sensex
| Current Share Price | : | ₹172.0 |
| Current MarketCap | : | ₹ 326.7 Cr |
| Updated EOD on | : | Aug 14,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATH BIOGENES (INDIA) | -1.4% |
-13.6% |
-20.2% |
| SENSEX | -0% |
-2.4% |
1.2% |
NATH BIOGENES (INDIA) related INDICES
No BSE index found!
No NSE index found
You may also like the below Video Courses
FAQ about NATH BIOGENES (INDIA) Financials
How the annual revenues of NATH BIOGENES (INDIA) have changed ?
The Revenues of NATH BIOGENES (INDIA) have increased by 9.71% YoY .
How the Earnings per Share (EPS) of NATH BIOGENES (INDIA) have changed?
The Earnings Per Share (EPS) of NATH BIOGENES (INDIA) has decreased by -2.59 % YoY .
Check out Intrinsic Value of Peers of NATH BIOGENES (INDIA)
Compare Stock Analytics of Peers of NATH BIOGENES (INDIA)
BOMBAY BURMAH TRADING CORPORATION LTD vs KAVERI SEED COMPANY LTD vs VENKYS (INDIA) LTD
BOMBAY SUPER HYBRID SEEDS LTD vs INDO US BIOTECH LTD vs
BOMBAY BURMAH TRADING CORPORATION LTD vs KAVERI SEED COMPANY LTD vs VENKYS (INDIA) LTD
BOMBAY SUPER HYBRID SEEDS LTD vs INDO US BIOTECH LTD vs
